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Mucosal-­‐associated	   invariant	   T	   (MAIT)	   cells	   normally	   preserve	   gut	   barrier	   integrity,	   but	  
can	  switch	  their	  phenotype	  to	  play	  a	  pathogenic	  role	  in	  type	  1	  diabetes	  
The	   iterative	  dialogue	  between	  gut	  microbiota	  and	   the	   immune	  system	  has	  emerged	  as	  a	  
dominant	  theme	  in	  immunology	  research.	  	  But	  how	  microbial	  cues	  shape	  the	  development	  
of	  immune-­‐mediated	  disease	  remains	  unclear.	  In	  this	  issue	  of	  Nature	  Immunology,	  Rouxel	  et	  
al.	   suggest	   that	   mucosal-­‐associated	   invariant	   T	   (MAIT)	   cells	   responding	   to	   microbial	  
metabolites	  can	  influence	  the	  development	  of	  type	  1	  diabetes1.	  
Type	  1	  diabetes	  (T1D)	  is	  a	  complex	  autoimmune	  disease	  that	  leads	  to	  destruction	  of	  insulin-­‐
producing	   pancreatic	   β-­‐cells	   and	   a	   requirement	   for	   lifelong	   exogenous	   insulin	  
administration2.	  While	  the	  pathophysiology	  of	  T1D	  is	  still	  not	  entirely	  understood,	  a	  growing	  
body	   of	   evidence	   implicates	   alterations	   in	   gut	   permeability	   and	   changes	   to	   the	   intestinal	  
microbiota	  as	  early	  events	  in	  disease	  development3,4.	  MAIT	  cells	  are	  innate-­‐like	  T	  cells	  that	  
are	  enriched	   in	  the	   intestine	  and	  express	  a	  T	  cell	  receptor	  (TCR)	  composed	  of	  an	   invariant	  
TCRα	  chain	  (TRAV1-­‐2-­‐TRAJ33/12/20	  in	  humans	  and	  TRAV1-­‐TRAJ33	  in	  mice)	  coupled	  with	  a	  
limited	  repertoire	  of	  TCRβ	  chains.	  This	  endows	  them	  with	  the	  capacity	  to	  recognise	  bacteria-­‐
derived	   riboflavin	   precursors	   presented	   by	   the	   major-­‐histocompatibility-­‐complex-­‐class-­‐I-­‐
related	   protein	   1	   (MR1)5.	   MAIT	   cell	   development	   is	   impaired	   in	   germ-­‐free	   mice6,	  
emphasizing	  their	  intimate	  connection	  with	  commensal	  microflora.	  
To	   probe	   the	   possible	   involvement	   of	  MAIT	   cells	   in	   T1D,	   Rouxel	  et	   al.	   first	   assessed	   their	  
number	  in	  the	  peripheral	  blood	  of	  children	  who	  had	  developed	  T1D	  within	  the	  last	  10	  days.	  
MAIT	   cell	   frequencies	   were	   significantly	   reduced	   in	   these	   children	   compared	   with	   age-­‐
matched	   controls	   and	   their	   phenotype	  was	   also	   distinct,	  with	   higher	   CD25	   and	   PD-­‐1	   and	  
lower	  CCR6	  and	  CD56	  than	  in	  control	  children.	  In	  addition,	  PMA-­‐ionomycin	  stimulated	  MAIT	  
cells	   from	   children	   with	   recent	   onset	   T1D	   produced	   less	   IFN-­‐γ	   but	   more	   TNF,	   IL-­‐4	   and	  
Granzyme	   B.	   	   Remarkably,	  measurement	   of	   just	   4	  markers	   (CCR6,	   CD25,	   PD-­‐1,	   CD56)	   on	  
MAIT	   cells	   in	   the	   blood	  was	   sufficient	   to	   define	   a	   predictive	   diagnostic	  model	   capable	   of	  
distinguishing	  the	  newly	  diabetic	  children	  from	  healthy	  controls.	  	  
Curiously,	   the	  authors	   identified	  a	   relationship	  between	  MAIT	  cell	  Granzyme	  B	  expression	  
and	   age	   of	   T1D	   diagnosis,	   with	   a	   young	   age	   at	   diagnosis	   being	   associated	   with	   high	  
frequencies	   of	   Granzyme	   B+	   MAIT	   cells.	   	   This	   is	   interesting	   in	   the	   light	   of	   the	   growing	  
recognition	  that	  children	  diagnosed	  young	  appear	  to	  show	  a	  more	  aggressive	  disease	  course	  
and	  have	  fewer	  insulin-­‐expressing	  pancreatic	  islets	  at	  diagnosis7.	  Spurred	  on	  by	  this	  finding,	  
the	   authors	   began	   to	   wonder	   whether	   MAIT	   cells	   could	   use	   their	   cytotoxic	   potential	   to	  
directly	   contribute	   to	   pancreatic	   β-­‐cell	   death.	   	   Staging	   the	   perfect	   crime	   scene,	   they	   co-­‐
cultured	  purified	  MAIT	  cells	  with	  the	  human	  β-­‐cell	  line	  EndoC-­‐βH1,	  throwing	  in	  the	  MAIT	  cell	  
ligand	   5-­‐OP-­‐RU	   to	   initiate	   interactions.	   However,	   the	   anticipated	   killing	   spree	   never	  
materialised.	  	  Mindful	  that	  cell	  surface	  MR1	  levels	  are	  low	  on	  most	  cell	  types8,	  the	  authors	  
added	   inflammatory	  cytokines	   to	   the	  mix,	  opting	   for	   IL-­‐1β,	   IFN-­‐γ,	  and	  TNF	  since	   these	  are	  
typically	  present	  in	  inflamed	  islets	  in	  the	  T1D	  setting.	  	  Strikingly,	  MR1	  expression	  rose	  on	  the	  
EndoC-­‐βH1	  cells	  and	  the	  MAIT	  cells	  became	  activated	  and	  degranulated,	  eliciting	  killing	  that	  
was	  dependent	  on	  ligand	  dose	  and	  blocked	  by	  anti-­‐MR1	  antibodies.	  Future	  work	  is	  needed	  
to	   assess	   whether	   MAIT	   cells	   are	   present	   at	   the	   scene	   of	   the	   crime	   in	   the	   pancreas	   of	  
diabetic	   humans,	   and	   whether	   primary	   β-­‐beta	   cells	   can	   indeed	   express	   MR1	   in	   situ.	  
Nevertheless,	   these	   provocative	   findings	   suggest	   the	   potential	   for	   MAIT	   cells	   to	   directly	  
participate	  in	  the	  process	  of	  β-­‐cell	  destruction	  (Figure	  1).	  
In	  mice,	  MAIT	   cells	   comprise	   only	   ~0.1%	   of	   peripheral	   blood	   T	   cells	   compared	   to	   ~6%	   in	  
humans9,	  and	  until	  recently	  the	  study	  of	  murine	  MAIT	  cells	  was	  limited	  by	  a	  lack	  of	  sensitive	  
identification	  methods.	  However,	  the	  development	  of	  riboflavin	  derivative	  5-­‐OP-­‐RU-­‐loaded	  
MR1	   tetramers	   has	   allowed	   researchers	   to	   recapitulate	   in	   mouse	   models	   many	   of	   the	  
observations	  previously	  made	  in	  human	  MAIT	  cells9.	  	  Taking	  advantage	  of	  this	  research	  tool,	  
Rouxel	  et	  al.	   turned	  to	  the	  NOD	  mouse	  model	  of	  T1D.	   In	  general	   the	   frequencies	  of	  MAIT	  
cells	  were	   lower	   in	  NOD	  than	   in	   the	  C57BL/6	  mice	   that	  were	  used	  as	  a	  control,	  and	  were	  
even	  below	  detection	  levels	  in	  the	  blood.	  	  Interestingly	  however	  MAIT	  cells	  were	  present	  in	  
the	   pancreatic	   islets	   of	   NOD	   mice	   and	   were	   more	   abundant	   in	   the	   ileum	   of	   NOD	   than	  
C57BL/6	  animals.	  	  	  
One	  limitation	  of	  human	  studies	  is	  the	  understandable	  reliance	  on	  peripheral	  blood	  samples	  
and	   the	   inability	   to	   simultaneously	   explore	  multiple	   tissue	   sites.	   Taking	   advantage	   of	   the	  
mouse	  model,	  Rouxel	  et	  al.	  were	  able	  to	  gain	  a	  more	  comprehensive	  view	  of	  how	  MAIT	  cells	  
redistribute	   during	   disease	   development.	   	   Interestingly,	   progression	   to	   diabetes	   in	   NOD	  
mice	   was	   associated	  with	   a	   trend	   towards	   lower	  MAIT	   cell	   frequencies	   in	   the	   ileum	   and	  
spleen	   and	   a	   concomitant	   increase	   in	   the	   pancreatic	   lymph	   nodes	   and	   pancreatic	   islets.	  
Adoptive	   transfer	   experiments	   confirmed	   that	  MAIT	   cells	   could	   directly	  migrate	   from	   the	  
blood	   to	   the	   tissues,	  with	  a	   strong	  preference	   for	   the	   ileum	  over	   the	   islets	   in	  young	  NOD	  
mice,	  but	  a	  shift	  towards	  islet	  migration	  in	  older	  animals.	  	  
Most	   interesting	   was	   the	   change	   in	  MAIT	   cell	   phenotype	   during	   disease	   progression.	   	   In	  
16wk	  old	  mice,	  islet-­‐resident	  MAIT	  cells	  already	  expressed	  some	  Granzyme	  B,	  but	  in	  diabetic	  
animals	   levels	  were	  much	   higher	   and	   IFN-­‐γ	  was	   also	   produced.	   	   Conversely,	   in	   the	   ileum	  
MAIT	  cells	  produced	  IL-­‐22	  and	  IL-­‐17	  in	  16wk	  old	  mice	  but	  this	  was	  virtually	  extinguished	  in	  
diabetic	  animals.	  	  These	  kinetic	  data	  capture	  the	  shift	  in	  MAIT	  cell	  behaviour	  as	  they	  forsake	  
their	   role	   in	  gut	  homeostasis	   to	   join	   the	  conventional	  T	   cells	  waging	  war	   in	   the	   islets.	   	   So	  
what	  is	  the	  trigger	  for	  this	  shift?	  	  The	  authors	  noted	  a	  decrease	  in	  IL-­‐23	  levels	  in	  the	  ileum	  at	  
diabetes	   onset	   which	   likely	   explains	   the	   drop	   in	   MAIT	   cell	   IL-­‐22	   and	   IL-­‐17	   production.	  	  
Intriguingly	  this	  coincided	  with	  an	  increase	  in	  gut	  permeability,	  as	  measured	  by	  blood	  FITC-­‐
dextran	   levels	   after	   oral	   gavage,	   raising	   the	   possibility	   that	   MAIT	   cell	   alterations	   are	  
instructed	  by	  microbe-­‐derived	  ligands.	  
To	  directly	   test	   the	   role	  of	  MAIT	   cells	   in	  diabetes	  pathogenesis,	   the	   authors	  painstakingly	  
generated	  Mr1–/–	  NOD	  mice	  and	  compared	  them	  with	  co-­‐housed	  littermate	  Mr1+/–	  controls	  
to	  avoid	  differences	  in	  gut	  microbiota.	  The	  lack	  of	  MAIT	  cells	  in	  the	  absence	  of	  MR1	  led	  to	  
severely	   damaged	   gut	   epithelium,	   increased	   intestinal	   permeability	   and	   greater	   immune	  
activation	  resulting	  in	  significantly	  exacerbated	  disease.	  	  These	  data	  reveal	  a	  protective	  role	  
for	  MAIT	  cells	  in	  T1D	  development	  centering	  on	  their	  role	  in	  maintaining	  gut	  integrity.	  	  They	  
also	   indicate	   (unsurprisingly)	   that	   MAIT	   cells	   are	   not	   absolutely	   required	   for	   islet	  
destruction,	  or	  for	  sensing	  the	  loss	  of	  gut	  barrier	  integrity,	  even	  though	  they	  may	  contribute	  
to	  these	  processes.	  	  
One	   question	   arising	   from	   these	   studies	   echoes	   the	   classic	   chicken	   and	   egg	   conundrum:	  
Does	  impaired	  MAIT	  cell	  function	  trigger	  loss	  of	  gut	  integrity,	  or	  does	  a	  leaky	  gut	  stimulate	  
MAIT	   cell	   changes?	  Given	   the	   smorgasbord	   of	   susceptibility	   loci	   that	   influence	   real	  world	  
autoimmunity,	   it	   is	  easy	  to	  envisage	  that	  both	  scenarios	  might	  exist,	  with	  some	  individuals	  
harbouring	  single	  nucleotide	  polymorphisms	  that	  alter	  MAIT	  cell	  activation	  and/or	  homing	  
and	   others	   being	   genetically	   predisposed	   to	   increased	   gut	   permeability.	   A	   deeper	  
understanding	  of	  MAIT	  cell	  biology	  could	  potentially	  shed	  light	  on	  the	  association	  between	  
T1D	  and	  celiac	  disease,	  given	  the	  link	  to	  gut	  permeability	  in	  both	  conditions.	  	  
Arguably	   the	   most	   significant	   finding	   of	   the	   study	   was	   that	   MAIT	   cell	   changes	   could	   be	  
detected	   in	   humans	   even	   before	   the	   development	   of	   diabetes.	   Accordingly,	   relatives	   of	  
people	   with	   T1D	   with	   at	   least	   2	   autoantibodies	   had	   blood	   MAIT	   cells	   showing	   similar	  
phenotypic	   alterations	   to	   those	   seen	   in	   the	   new	   onset	   patients.	   Since	   risk	   profiles	   differ	  
between	  relatives	  with	  a	  single	  autoantibody	  versus	  multiple	  autoantibodies,	  it	  would	  be	  of	  
great	   interest	   to	   compare	   MAIT	   cell	   phenotypes	   between	   these	   groups	   and	   assess	   the	  
relationship	  with	  disease	  progression.	   	  Perhaps	  tracking	  MAIT	  cells	  can	  help	  discern	  which	  
individuals	  in	  the	  "at	  risk"	  category	  will	  go	  on	  to	  develop	  disease.	  
More	   generally,	   the	   findings	   add	   to	   a	   growing	   body	   of	   work	   highlighting	   environmental	  
influences	  on	  autoimmune	  disease	  development.	  Over	   the	  past	  decades,	   the	   incidence	  of	  
T1D	   has	   increased	   dramatically	   at	   a	   rate	   that	   suggests	   involvement	   of	   factors	   beyond	  
genetic	   change.	   At	   the	   same	   time,	   it	   has	   become	   apparent	   that	   the	   immune	   system	   is	  
shaped	   to	   a	   surprising	   extent	   by	   non-­‐heritable	   influences10.	   	   The	  microbiota	   undoubtedly	  
exerts	   a	   major	   influence	   on	   immunity,	   with	   recent	   suggestions	   that	   bacteria	   can	   even	  
translocate	   from	   the	   gut	   to	   the	   pancreatic	   lymph	   nodes	   in	   a	  mouse	  model	   of	   diabetes11.	  	  
The	  new	   findings	   from	  Rouxel	  et	  al.	   position	  MAIT	   cells	   at	   the	  nexus	  between	  microbiota	  
and	  immune	  function,	   limiting	  commensal	  dissemination	  by	  preserving	  gut	  integrity	  and	  in	  
turn	   being	   stimulated	   by	  microbial	   products.	   Tantalisingly,	   although	  MAIT	   cells	   recognise	  
bacterial	   metabolites,	   recent	   evidence	   suggests	   they	   are	   also	   activated	   during	   viral	  
infections12.	  	  Given	  the	  putative	  links	  between	  viral	  infection	  and	  T1D,	  this	  promises	  to	  be	  an	  
active	  area	  of	  future	  investigation.	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Figure	  1:	  Dual	  role	  of	  MAIT	  cells	  in	  T1D.	  MAIT	  cells	  are	  enriched	  in	  the	  gut	  and	  recognize	  
bacterial	  metabolites.	  They	  produce	  IL-­‐17A	  and	  IL-­‐22	  which	  are	  important	  for	  the	  
maintenance	  of	  gut	  barrier	  integrity.	  Changes	  in	  gut	  permeability	  and	  intestinal	  microbiota	  
have	  been	  linked	  to	  T1D	  development	  in	  humans.	  	  NOD	  mice	  lacking	  MAIT	  cells	  show	  
increased	  gut	  permeability	  and	  exacerbated	  disease,	  suggesting	  MAIT	  cells	  can	  protect	  from	  
T1D.	  	  In	  NOD	  mice,	  progression	  to	  diabetes	  is	  associated	  with	  decreased	  production	  of	  IL-­‐
17A	  and	  IL-­‐22	  from	  MAIT	  cells	  in	  the	  ileum	  and	  an	  accumulation	  of	  IFN-­‐γ	  and	  Granzyme	  B	  
producing	  MAIT	  cells	  in	  the	  pancreatic	  islets.	  Human	  MAIT	  cells	  can	  directly	  kill	  a	  human	  β-­‐
cell	  line	  suggesting	  a	  potential	  pathogenic	  role	  in	  T1D.	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